<code id='596F3873A1'></code><style id='596F3873A1'></style>
    • <acronym id='596F3873A1'></acronym>
      <center id='596F3873A1'><center id='596F3873A1'><tfoot id='596F3873A1'></tfoot></center><abbr id='596F3873A1'><dir id='596F3873A1'><tfoot id='596F3873A1'></tfoot><noframes id='596F3873A1'>

    • <optgroup id='596F3873A1'><strike id='596F3873A1'><sup id='596F3873A1'></sup></strike><code id='596F3873A1'></code></optgroup>
        1. <b id='596F3873A1'><label id='596F3873A1'><select id='596F3873A1'><dt id='596F3873A1'><span id='596F3873A1'></span></dt></select></label></b><u id='596F3873A1'></u>
          <i id='596F3873A1'><strike id='596F3873A1'><tt id='596F3873A1'><pre id='596F3873A1'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:knowledge    Page View:32
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In